This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Papandreou, C. N. Articles by Logothetis, C. J. Search for Related Content PubMed PubMed Citation Articles by Papandreou, C. N. Articles by Logothetis, C. J. Social Bookmarking                            What's this?

Results of a Phase II Study With Doxorubicin, Etoposide, and Cisplatin in Patients With Fully Characterized Small-Cell Carcinoma of the Prostate

From the Departments of Genitourinary Medical Oncology, Biostatistics, and Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030.

Address reprint requests to Christos N. Papandreou, MD, PhD, The University of Texas M.D. Anderson Cancer Center, Department of Genitourinary Medical Oncology, 1515 Holcombe Blvd, Box 427, Houston, TX 77030; email: cpapandr{at}notes.mdacc.tmc.edu

PURPOSE: To determine the activity and toxicity of doxorubicin in combination with cisplatin and etoposide in patients with small-cell prostate carcinoma (SCPCa) and to characterize the clinicopathologic features of SCPCa.

PATIENTS AND METHODS: Patients with SCPCa (pure or mixed), measurable disease, good organ function, and no prior treatment with doxorubicin, etoposide, or cisplatin were treated every 4 weeks with doxorubicin 50 mg/m² as a 24-hour intravenous (IV) infusion followed by etoposide 120 mg/m²/d and cisplatin 25 mg/m²/d IV on days 2 to 4.

RESULTS: Thirty-eight patients (36 assessable for response) were treated for a median of four cycles. Twenty-nine (81%) of 36 patients had prior hormonal therapy. Study patients had visceral metastases, lytic bone disease, and relatively low serum prostate-specific antigen (PSA). We observed 22 partial responses (response rate, 61% in an intent-to-treat analysis); toxicity was severe (grade 3 or 4 neutropenia 100%, thrombocytopenia 66%, mucositis 21%, and infection 68%). Three patients died of toxicity. Median time to progression and overall survival time were 5.8 months and 10.5 months, respectively. Performance status, serum albumin, and number of organs involved (but not PSA, carcinoembryonic antigen, or neuroendocrine markers) were predictors of survival.

CONCLUSION: SCPCa presents unique clinicopathologic features. Addition of doxorubicin to the etoposide/cisplatin regimen caused higher toxicity in this patient population and failed to improve outcome. Given these results, we do not recommend further development of this regimen for patients with SCPCa. Improvement in therapy will come from understanding the biology of SCPCa progression and integrating new targeted therapies into the treatment of SCPCa.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F. Vignani, L. Russo, M. Tucci, M. Motta, G. Vellani, M. Tampellini, M. Papotti, L. Dogliotti, and A. Berruti Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen Ann. Onc., December 1, 2009; 20(12): 2019 - 2020. [Full Text] [PDF]

				Y. Loriot, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, A. Bossi, and K. Fizazi Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features Ann. Onc., April 1, 2009; 20(4): 703 - 708. [Abstract] [Full Text] [PDF]

				C. J. Logothetis and R. Millikan Chemotherapy for Advanced Prostate Cancer: 25 Years Later J. Clin. Oncol., May 20, 2008; 26(15): 2423 - 2424. [Full Text] [PDF]

				C. J. Anker, C. Dechet, J. C. Isaac, W. Akerley, and D. C. Shrieve Small-Cell Carcinoma of the Prostate J. Clin. Oncol., March 1, 2008; 26(7): 1168 - 1171. [Full Text] [PDF]

				J. D. Hainsworth, D. R. Spigel, S. Litchy, and F. A. Greco Phase II Trial of Paclitaxel, Carboplatin, and Etoposide in Advanced Poorly Differentiated Neuroendocrine Carcinoma: A Minnie Pearl Cancer Research Network Study J. Clin. Oncol., August 1, 2006; 24(22): 3548 - 3554. [Abstract] [Full Text] [PDF]

				M. Mimeault and S. K. Batra Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies Carcinogenesis, January 1, 2006; 27(1): 1 - 22. [Abstract] [Full Text] [PDF]

				J. R. Brown, T. J. Wieczorek, K. Shaffer, and R. Salgia Small-Cell Cancers, and an Unusual Reaction to Chemotherapy: CASE 1. EXTRAPULMONARY SMALL-CELL CARCINOMA ARISING IN THE PROSTATE J. Clin. Oncol., June 15, 2003; 21(12): 2437 - 2438. [Full Text] [PDF]